HemaSphere
(Jun 2022)
P746: COMBINATION OF RAS/MAPK MODULATOR AND AZACITIDINE AFFECTS HISTONE MARKS AND IMPACTS THE INNATE IMMUNE SIGNALING PATHWAY IN THE MDS-L CELL LINE
- R. Rai,
- F. Patel,
- J. Feld,
- S. Melana,
- S. Navada,
- R. Odchimar-Reissig,
- E. Demakos,
- E. P. Reddy,
- A. Horowitz,
- L. Silverman
Affiliations
- R. Rai
- 1 Division of Hematology and Medical Oncology
- F. Patel
- 1 Division of Hematology and Medical Oncology
- J. Feld
- 1 Division of Hematology and Medical Oncology
- S. Melana
- 1 Division of Hematology and Medical Oncology
- S. Navada
- 1 Division of Hematology and Medical Oncology
- R. Odchimar-Reissig
- 1 Division of Hematology and Medical Oncology
- E. Demakos
- 1 Division of Hematology and Medical Oncology
- E. P. Reddy
- 2 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States of America
- A. Horowitz
- 2 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States of America
- L. Silverman
- 1 Division of Hematology and Medical Oncology
- DOI
-
https://doi.org/10.1097/01.HS9.0000845868.83865.0c
- Journal volume & issue
-
Vol. 6
pp.
641
– 642
WeChat QR code